Pharmacokinetic and Pharmacodynamic Profiles of Pretomanid, Delamanid, and Bedaquiline in a BALB/c Mouse Model of Central Nervous System Tuberculosis - Takeaways - MDSpire

Pharmacokinetic and Pharmacodynamic Profiles of Pretomanid, Delamanid, and Bedaquiline in a BALB/c Mouse Model of Central Nervous System Tuberculosis

  • By

  • Hui Zhu

  • Yangxue Ye

  • Lei Fu

  • Weiyan Zhang

  • Bin Wang

  • Xi Chen

  • Yu Lu

  • February 12, 2026

  • 0 min

Share

  • 1

    Tuberculosis remains the leading infectious disease killer globally, with central nervous system tuberculosis (CNS-TB) being particularly lethal.

  • 2

    New anti-tuberculosis drugs like pretomanid, delamanid, and bedaquiline show promise for treating multidrug-resistant tuberculosis.

  • 3

    Current treatment guidelines for CNS-TB lack clarity on the use of pretomanid, delamanid, and bedaquiline, necessitating further research.

  • 4

    The study investigates the pharmacokinetic and pharmacodynamic properties of these drugs in a BALB/c mouse model of CNS-TB.

  • 5

    Findings from this research could inform potential treatment strategies for CNS-TB using these newer anti-tuberculosis agents.

Original Source(s)

Pharmacokinetic and Pharmacodynamic Profiles of Pretomanid, Delamanid, and Bedaquiline in a BALB/c Mouse Model of Central Nervous System Tuberculosis

  • by Hui Zhu, Yangxue Ye, Lei Fu, Weiyan Zhang, Bin Wang, Xi Chen, Yu Lu

  • February 12, 2026

Related Content

UTI Prophylaxis Raises Resistance Risk

Study finds more resistance on culture, no significant rise in severe infections

The Loan Cap That Could Shrink the Doctor Pipeline

New federal limits on medical school borrowing may quietly reshape who becomes a physician—and where they practice.

Corallopyronin A exhibits potent activity against staphylococci including MRSA and isolates from prosthetic infections